Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a coverage agreement with a second major group purchasing organization, effective June 1, 2026, expanding access to TONMYA(R) for an additional 17 million U.S. commercial lives. The agreement increases total commercial coverage for the company’s fibromyalgia treatment to approximately 52 million lives, representing about 29% of the estimated 177 million commercially insured individuals in the United States.
According to the company, TONMYA is also now available through Medicaid programs covering approximately 75 million lives, while discussions with Medicare continue. TONMYA, a non-opioid analgesic designed for daily bedtime administration and long-term use, was launched commercially following an earlier coverage agreement announced in May that provided access to approximately 35 million commercial lives.
The expansion of TONMYA coverage is significant for patients with fibromyalgia, a condition characterized by widespread musculoskeletal pain. TONMYA is the first new treatment for fibromyalgia in more than 15 years, offering a non-opioid option for long-term management. The increased access may reduce the burden on patients who previously had limited treatment options.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
The news highlights Tonix’s progress in broadening patient access to TONMYA, which could translate into increased revenue and market penetration. For investors, the expansion into a larger share of the commercial insurance market is a positive indicator of commercial traction. However, the company continues to face the challenge of securing Medicare coverage, which would further expand the patient population.
For more information, visit the company’s newsroom at https://ibn.fm/TNXP.
